The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-terminal proBNP in end-stage renal disease patients on dialysis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Nakagawa, Yasuaki ^a   Nishikimi, Toshio ^a   Kuwahara, Koichiro ^a   Yasuno, Shinji ^b   Kinoshita, Hideyuki ^a   Kuwabara, Yoshihiro ^a   Nakao, Kazuhiro ^a   Minami, Takeya ^a   Yamada, Chinatsu ^a   Ueshima, Kenji ^b   Ikeda, Yoshihiro ^c   Okamoto, Hiroyuki ^d   Horii, Kazukiyo ^d   Nagata, Kiyoshi ^d   Kangawa, Kenji ^e   Minamino, Naoto ^e   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c Midorikawa Clinic of Neurology   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED PROTEIN; INSULIN; NITRATE; PARATHYROID HORMONE; STATIN (PROTEIN); PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; IMMUNOASSAY; MALE; MOLECULAR WEIGHT; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; AGED; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DEVICES; ECHOCARDIOGRAPHY; FLUID THERAPY; GLYCOSYLATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROGNOSIS;

AGED; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; FLUID THERAPY; GLYCOSYLATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RENAL DIALYSIS;

EID: 84899787599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092314     Document Type: Article

References (34)

1. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203. (Pubitemid 24203680)
2. Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57: 131-140.
3. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69: 318-328. (Pubitemid 43098788)
4. Weber M, Dill T, Deetjen A, Neumann T, Ekinci O, et al. (2006) Left ventricular adaptation after atrial septal defect closure assessed by increased concentrations of N-terminal pro-brain natriuretic peptide and cardiac magnetic resonance imaging in adult patients. Heart 92: 671-675.
5. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, et al. (1996) Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28: 22-30. (Pubitemid 26231085)
6. Nishikimi T, Futoo Y, Tamano K, Takahashi M, Suzuki T, et al. (2001) Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 37: 1201-1208. (Pubitemid 32525156)
7. Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50: 2357-2368. (Pubitemid 50011582)
8. Nishikimi T, Minamino N, Ikeda M, Takeda Y, Tadokoro K, et al. (2010) Diversity of molecular forms of plasma brain natriuretic peptide in heart failure- different proBNP-108 to BNP-32 ratios in atrial and ventricular overload. Heart 96: 432-439.
9. Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, et al. (2013) Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. PLoS One 8: e53233.
10. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, et al. (2006) The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 451: 160-166.
11. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, et al. (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49: 1071-1078. (Pubitemid 46349497)
12. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, et al. (2008) Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 54: 866-873. (Pubitemid 351671597)
13. Jackson S (1985) Anatomy & Physiology for Nurses. Nurses' Aids Series (9th ed.).
14. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, et al. (2012) The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 98: 152-161.
15. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, et al. (2008) Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 54: 619-621. (Pubitemid 351348175)
16. Hammerer-Lercher A, Halfinger B, Sarg B, Mair J, Puschendorf B, et al. (2008) Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 54: 858-865. (Pubitemid 351671596)
17. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, et al. (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350: 1349-1353. (Pubitemid 28036901)
18. Davis M, Espiner E, Richards G, Billings J, Town I, et al. (1994) Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343: 440-444. (Pubitemid 24059585)
19. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, et al. (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95: 948-954. (Pubitemid 40487743)
20. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161-167. (Pubitemid 34764819)
21. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, et al. (1997) Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 47: 287-296. (Pubitemid 27395959)
22. Jourdain P, Funck F, Bellorini M, Guillard N, Loiret J, et al. (2003) Bedside Btype natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 5: 155-160. (Pubitemid 36383622)
23. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, et al. (1996) Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28: 988-994. (Pubitemid 26415815)
24. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, et al. (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43: 416-422. (Pubitemid 38167702)
25. Niizuma S, Iwanaga Y, Yahata T, Tamaki Y, Goto Y, et al. (2009) Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. Clin Chem 55: 1347-1353.
26. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, et al. (2007) N-terminal probrain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 18: 321-330. (Pubitemid 46053444)
27. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, et al. (2001) Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59: 1559-1566. (Pubitemid 32281248)
28. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, et al. (2007) N-terminal pro brain natriuretic peptide predicts mortality in patients with endstage renal disease in hemodialysis. Kidney Int 71: 548-554. (Pubitemid 46398682)
29. Satyan S, Light RP, Agarwal R (2007) Relationships of N-terminal pro-Bnatriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 50: 1009-1019. (Pubitemid 350122814)
30. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, et al. (2001) Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 76: 1111-1119. (Pubitemid 33032388)
31. Niizuma S, Iwanaga Y, Yahata T, Goto Y, Kita T, et al. (2009) Plasma B-type natriuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients. Nephrol Dial Transplant 24: 597-603.
32. Sivalingam M, Suresh M, Farrington K (2011) Comparison of B-type natriuretic peptide and NT proBNP as predictors of survival in patients on high-flux hemodialysis and hemodiafiltration. Hemodial Int 15: 359-365.
33. Schluter KD, Piper HM (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37: 34-41.
34. Sheen V, Bhalla V, Tulua-Tata A, Bhalla MA, Weiss D, et al. (2007) The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 153: 244 e241-245.